In vitro, HER2-TTC showed potent cytotoxicity in various HER2-expressing cancer cell lines...In vivo, HER2-TTC demonstrated dose-dependent antitumor efficacy in subcutaneous xenograft models….These results demonstrate proof-of-concept for TAT in the treatment of patients with HER2-positive breast cancer, including cases where the tumor has metastasized to bone.